Compliance Requirements and Quality Control System for Reverse Transcriptase Raw Materials in IVD Registration

General requirements for key raw materials in IVD registration

Reverse transcriptase is generally considered a key raw material in nucleic acid detection in vitro diagnostic reagents. Registration review generally requires the provision of raw material source, preparation process, quality control indicators, and supplier information. Manufacturers need to clarify the biological source, purity, activity units, and nuclease-free residues of the reverse transcriptase used, as well as its general performance, and explain its impact on the performance of the final product. For purchased raw materials, supplier qualifications and quality agreements are also among the points of concern in review.

Performance verification content for reverse transcriptase raw materials

Before being incorporated into diagnostic reagent production, reverse transcriptase raw materials need to undergo systematic verification. Common verification items include: evaluating reverse transcription efficiency using an exogenous RNA template; assessing background amplification using no-template controls and negative samples; confirming the linear range using positive templates with different concentration gradients; and, when necessary, verifying tolerance to common sample matrices and inhibitors. The verification results should support the sensitivity and specificity claims in the product instructions.

Supplier management and change control

Changes in suppliers of reverse transcriptase raw materials, adjustments to production processes, or modifications to formulations may affect reagent performance. Manufacturers should establish supplier admission and periodic evaluation mechanisms and retain quality records for key materials. Any changes involving reverse transcriptase replacement, adjustment of activity units, or changes in the buffer system generally require risk assessment and performance comparison, with supplementary verification when necessary, to ensure product quality stability.

Stability studies and shelf-life setting

The stability of reverse transcriptase varies considerably between liquid and lyophilized states. Stability studies usually cover real-time stability, accelerated stability, and transport stability. Studies should simulate actual storage and transport conditions and examine trends in activity decline, appearance changes, and effects on detection performance. Shelf-life setting needs to be based on sufficient data and should consider stability after opening or storage conditions after reconstitution, avoiding reliance solely on empirical judgment.

Common risk points in compliance systems

Common risks include activity fluctuations between raw material lots, exogenous nucleic acid contamination, lack of supplier audits, and incomplete verification data. Manufacturers should incorporate reverse transcriptase management into the medical device quality management system and clearly define procurement, acceptance, release, and change processes. For clinical detection reagents, the continued stability and traceability of raw materials are the basis for ensuring reliable results.